Parallax Volatility Advisers
ABCL icon

Parallax Volatility Advisers’s AbCellera Biologics ABCL Stock Holding History

Parallax Volatility Advisers’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-86,400
Closed -$854K – 2826
2022
Q3 		$854K Buy
+86,400
New +$948K ﹤0.01% 1786

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallax Volatility Advisers's ABCL Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of AbCellera Biologics (ABCL) in Q4 2022, closing a stake of 57,430 shares — an estimated $568K sold.

Parallax Volatility Advisers first reported a position in ABCL in Q3 2022 and held it in 1 quarter. The position peaked at $568K in Q3 2022. 203 funds tracked by Wall St. Rank hold ABCL as of Q4 2022.

  • Parallax Volatility Advisers reported no remaining AbCellera Biologics position as of Q4 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 57,430 AbCellera Biologics shares in Q4 2022, an estimated $568K.
  • Parallax Volatility Advisers first reported a position in AbCellera Biologics in Q3 2022 and held it in 1 quarter.
  • Parallax Volatility Advisers's AbCellera Biologics position peaked at $568K in Q3 2022.
  • 203 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.